ABBV Stock AbbVie Inc.
US · NYSELast in our picks 2026-10-26 — not in the current list; analysis below is from that screen
Immunology growth, aesthetics recovery, and dividend-supported cash flows offer defensive upside.
Future value: $282.61 (-1.06%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Pipeline replacement progress and stable institutional ownership.
- ▸Above 50-day MA (+7.33%)
- ▸Above 200-day MA — long-term uptrend
- ▸Near 52-week high (94.3% of range) — strength
- ▾Trading above its price target — limited upside
Is ABBV a buy right now?
Trend: ABBV is trading above the 50-day average (+7.34%), RSI 52 — neutral momentum, with a 3-month return of +11.18%.
Valuation & quality: AbbVie Inc. trades on a trailing P/E of 81.0, forward P/E 17.7, PEG 0.58; fundamentals show net margin 9.8%, revenue growth 10.2% year on year.
Analyst consensus: 28 analysts have a mean 12-month price target of $284.79 (-0.7% vs the last close; range $200.00 – $328.00), consensus rating “buy”.
Income: trailing dividend yield 2.42%.
Our screen: BUY (score 2) — Immunology growth, aesthetics recovery, and dividend-supported cash flows offer defensive upside.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -6.30% | -2.80% | +3.00% | +15.60% | -0.30% | +2.20% | +2.00% | +9.20% |
Fundamentals
Analyst price target
Technical signals
About AbbVie Inc.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
Sector: Healthcare · Industry: Drug Manufacturers - General · United States · 57,000 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.